Patent · US Expired

Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

US7771748B2 · kind B2 · utility

0Cited by
20References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 20, 2002
Grant dateAug 10, 2010
Priority date
Expiry dateOct 28, 2025

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02P20/582
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.